Skip to main content

Advertisement

SpringerLink
Log in

The role of new oral anticoagulants in orthopaedics: an update of recent evidence

  • General Review • GENERAL ORTHPAEDICS - SURGERY
  • Published:
European Journal of Orthopaedic Surgery & Traumatology Aims and scope Submit manuscript

Abstract

Rivaroxaban, dabigatran, apixaban and edoxaban are the four available new oral anticoagulants (NOAC) which are currently approved for venous thromboembolism prophylaxis after total hip and knee replacement. Large phase 3 and phase 4 studies comparing NOAC with low molecular weight heparins have shown similar results regarding the efficacy and safety of these two categories of anticoagulants. Management of bleeding complications is a matter of great significance. Three reversal agents have been developed: idarucizumab, andexanet alfa and ciraparantag. Idarucizumab is now commercially available. Regarding the perioperative management of NOAC, two main scientific groups have published their own recommendations. The European Heart Rhythm Association recommends 48-h period of stoppage preoperatively for factor Xa inhibitors and at least 3 or 4 days for dabigatran, while the French Study Group on Thrombosis and Haemostasis recommends 5-day discontinuation for all NOAC. Conventional clot tests can only be used as rough indicators for laboratory assessment of the activity of NOAC. Specific laboratory tests have been developed for more accurate measurements of NOAC blood levels, including a dilute thrombin time test (Hemoclot test) and the ecarin clot test for dabigatran and chromogenic anti-factor Xa assays for direct factor Xa inhibitors. Due to the beneficial properties of NOAC, these drugs are gaining ground in daily orthopaedic practice, and many studies are being conducted in order to extend the indications of these anticoagulants agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e278S–e325S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Francis C (2013) Prevention of VTE in patients having major orthopedic surgery. J Thromb Thrombolysis 35(3):359–367

    Article  CAS  PubMed  Google Scholar 

  3. Kurtz S, Ong E, Mowat F, Halpern M (2007) Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89:780–785

    PubMed  Google Scholar 

  4. Klauser W, Dütsch M (2013) Practical management of new oral anticoagulants after total hip or total knee arthroplasty. Musculoskelet Surg 97(3):189–197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rachidi S, Aldin E, Greenberg C, Sachs B, Streiff M, Zeidan A (2013) The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol 6(6):677–695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Friedman R (2011) Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics 34(10):795–804

    Article  PubMed  Google Scholar 

  7. Fuji T, Fujita S, Kawai Y et al (2015) Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thrombosis J 13(1):27

    Article  Google Scholar 

  8. Fuji T, Wang C, Fujita S et al (2014) Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 134(6):1198–1204

    Article  CAS  PubMed  Google Scholar 

  9. Fuji T, Fujita S, Kawai Y et al (2014) Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res 133(6):1016–1022

    Article  CAS  PubMed  Google Scholar 

  10. Mont M, Jacobs J (2011) AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. Am Acad Orthop Surg 19(12):777–778

    Article  Google Scholar 

  11. National Institute for Health and Clinical Excellence Venous thromboembolism: reducing the risk. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. 2010 (updated 2015). http://guidance.nice.org.uk/CG92/NICEGuidance/pdf/English

  12. Scotish Intercollegiate Guidelines Network (2010) Prevention and management of venous thromboembolism. http://www.sign.ac.uk/guidelines/fulltext/122/index.html

  13. National Health and Medical Research Council (NHMRC) (2009) Prevention of venous thromboembolism in patients in Patients Admitted to Australian Hopsitals. https://www.nhmrc.gov.au/guidelines-publications/cp115

  14. Thomas T, Ganetsky V, Spinler S (2013) Rivaroxaban: an oral factor Xa inhibitor. Clin Ther 35(1):4–27

    Article  CAS  PubMed  Google Scholar 

  15. Dale B, Chan N, Eikelboom J (2015) Laboratory measurement of the direct oral anticoagulants. Br J Haematol 172(3):315–336

    Article  PubMed  Google Scholar 

  16. Russell R, Hotchkiss W, Knight J, Huo M (2013) The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty. Thrombosis 2013:1–5

    Article  Google Scholar 

  17. Kwong L (2012) Rivaroxaban, an oral, direct factor Xa Inhibitor: a new option for thromboprophylaxis. Orthopedics 35(11):919

    Article  PubMed  Google Scholar 

  18. Kreutz R, Haas S, Holberg G et al (2016) Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. Br J Clin Pharmacol 81(4):724–734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Eriksson B, Borris L, Friedman R et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765–2775

    Article  CAS  PubMed  Google Scholar 

  20. Kakkar A, Brenner B, Dahl O et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31–39

    Article  CAS  PubMed  Google Scholar 

  21. Lassen M, Ageno W, Borris L et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358(26):2776–2786

    Article  CAS  PubMed  Google Scholar 

  22. Turpie A, Lassen M, Davidson B et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676):1673–1680

    Article  CAS  PubMed  Google Scholar 

  23. Turpie A, Haas S, Kreutz R et al (2013) A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost 111(1):94–102

    Article  PubMed  Google Scholar 

  24. Cao Y, Zhang J, Shen H, Jiang Y (2010) Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 66(11):1099–1108

    Article  CAS  PubMed  Google Scholar 

  25. Turpie A, Lassen M, Eriksson B et al (2010) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thromb Haemost 105(3):444–453

    Article  PubMed  Google Scholar 

  26. Huisman MV, Quinlan DJ, Dahl OE, Schulman S (2010) Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 3:652–660

    Article  PubMed  Google Scholar 

  27. Gomez-Outes A, Terleira-Fernandez A, Suarez-Gea M, Vargas-Castrillon E (2012) Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 344:e3675

    Article  PubMed  PubMed Central  Google Scholar 

  28. Russell R, Huo M (2013) Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. J Arthroplasty 28(9):1477–1481

    Article  PubMed  Google Scholar 

  29. Ning G, Kan S, Chen L, Shangguan L, Feng S, Zhou Y (2016) Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials. Sci Rep 6:23726

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Beyer-Westendorf J, Lützner J, Donath L et al (2012) Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery. Thromb Haemost 109(1):154–163

    Article  PubMed  Google Scholar 

  31. Lazo-Langner A, Fleet JL, McArthur E, Garg AX (2014) Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. J Thromb Haemost 12:1626–1635

    Article  CAS  PubMed  Google Scholar 

  32. Charters M, Frisch N, Wessell N, Dobson C, Les C, Silverton C (2015) Rivaroxaban versus enoxaparin for venous thromboembolism prophylaxis after hip and knee arthroplasty. J Arthroplasty 30(7):1277–1280

    Article  PubMed  Google Scholar 

  33. Heckmann M, Thermann H, Heckmann F (2015) Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty. Hämostaseologie 35(4):358–363

    Article  CAS  PubMed  Google Scholar 

  34. Wang J, Yen S, Kuo F, Lin P (2014) Thromboprophylaxis after minimally invasive total knee arthroplasty: a comparison of rivaroxaban and enoxaparin. Biomed J 37(4):199

    Article  PubMed  Google Scholar 

  35. Rath N, Goodson M, White S, Forster M (2013) The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement. Knee 20(6):397–400

    Article  CAS  PubMed  Google Scholar 

  36. Jensen C, Steval A, Partington P, Reed M, Muller S (2010) Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br 93(1):91–95

    Google Scholar 

  37. Jameson SS, Rymaszewska M, Hui AC, James P, Serrano-Pedraza I, Muller SD (2012) Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am 94:1554–1558

    Article  PubMed  Google Scholar 

  38. Chahal GS, Saithna A, Brewster M et al (2013) A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis. Ortop Traumatol Rehabil 15(2):125

    Article  PubMed  Google Scholar 

  39. Zou Y, Tian S, Wang Y, Sun K (2014) Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagul Fibrinolysis 25(7):660–664

    Article  CAS  PubMed  Google Scholar 

  40. Brimmo O, Glenn M, Klika A, Murray T, Molloy R, Higuera C (2016) Rivaroxaban use for thrombosis prophylaxis is associated with early periprosthetic joint infection. J Arthroplasty 31(6):1295–1298

    Article  PubMed  Google Scholar 

  41. Sindali K, Rose B, Soueid H, Jeer P, Saran D, Shrivastava R (2012) Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. Eur J Orthop Surg Traumatol 23(4):481–486

    Article  PubMed  Google Scholar 

  42. Lassen M, Haas S, Kreutz R, Mantovani L, Holberg G, Turpie A (2015) Rivaroxaban for thromboprophylaxis after fracture-related orthopedic surgery in routine clinical practice. Clin Appl Thromb/Hemost 22(2):138–146

    Article  Google Scholar 

  43. Du W, Zhao C, Wang J, Liu J, Shen B, Zheng Y (2015) Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. J Orthop Surg Res 23(10):78

    Article  Google Scholar 

  44. Camporese G, Bernardi E, Noventa F et al (2016) Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). Thromb Haemost 116(2):349–355

    Article  PubMed  Google Scholar 

  45. Levitan B, Yuan Z, Turpie A et al (2014) Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. VHRM 26(10):157–167

    Article  Google Scholar 

  46. Praxada (Dabigatran) Prescribing Information.Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014. http://Bidocs.Boehringer-Ingelheim.Com/Biwebaccess/Viewservlet.Ser?Docbase=Renetnt&Folderpath=/Prescribinginformation/Pis/Pradaxa/Pradaxa.Pdf

  47. Burness CB, McKeage K (2012) Dabigatran etexilate. Drugs 72(7):963–986

    Article  CAS  PubMed  Google Scholar 

  48. Eriksson B, Dahl O, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591):949–956

    Article  CAS  PubMed  Google Scholar 

  49. Eriksson B, Dahl O, Huo M et al (2011) Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). Thromb Haemost 105(4):721–729

    Article  CAS  PubMed  Google Scholar 

  50. Eriksson B, Dahl O, Rosencher N et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178–2185

    Article  CAS  PubMed  Google Scholar 

  51. Ginsberg JS, Davidson BL, Comp PC, Francis CW et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24(1):1–9

    Article  PubMed  Google Scholar 

  52. Eriksson B, Dahl O, Rosencher N et al (2015) Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials. Thrombos J 13:36

    Article  Google Scholar 

  53. Wolowacz S, Roskell N, Plumb J, Caprini J, Eriksson B (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb Haemost 101(1):77–85

    CAS  PubMed  Google Scholar 

  54. Rosencher N, Samama C, Feuring M et al (2016) Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting. Thrombos J 14:8

    Article  Google Scholar 

  55. Kendoff D (2011) Oral thromboprophylaxis following total hip or knee replacement: review and multicentre experience with dabigatran etexilate. Open Orthop J 5(1):395–399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bloch B, Patel V, Best A (2014) Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement. Bone Joint J 96(1):122–126

    Article  PubMed  Google Scholar 

  57. Matziolis D, Matziolis G, Perka C (2011) Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty. Arch Orthop Trauma Surg 131(12):1739–1743

    Article  PubMed  Google Scholar 

  58. Gombár C, Horvath G, Gálity H, Sisák K, Tóth K (2014) Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty. Arch Orthop Trauma Surg 134(4):449–457

    Article  PubMed  Google Scholar 

  59. Mommsen P, Doering M, Egidy C, Gehrke T, Krettek C, Kendoff D (2014) Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty. Technol Health Care 22(6):901–908

    PubMed  Google Scholar 

  60. Aikens G (2014) New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop 5(3):188–203

    Article  PubMed  PubMed Central  Google Scholar 

  61. Harder S, Graff J (2013) Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 69(9):1617–1633

    Article  CAS  PubMed  Google Scholar 

  62. Lassen M, Raskob G, Gallus A, Pineo G, Chen D, Portman R (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361(6):594–604

    Article  CAS  PubMed  Google Scholar 

  63. Lassen M, Raskob G, Gallus A, Pineo G, Chen D, Hornick P (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717):807–815

    Article  CAS  PubMed  Google Scholar 

  64. Lassen M, Gallus A, Raskob G, Pineo G, Chen D, ramirez L (2010) apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487–2498

    Article  CAS  PubMed  Google Scholar 

  65. Huang J, Cao Y, Liao C, Wu L, Gao F (2011) Apixaban versus enoxaparin in patients with total knee arthroplasty. Thromb Haemost 105(2):245–253

    Article  CAS  PubMed  Google Scholar 

  66. Aryal M, Pandit A, Ghimire S et al (2015) Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery. J Community Hosp Intern Med Perspect 5(4):27889

    Article  PubMed  Google Scholar 

  67. Villa L, Malone D, Ross D (2013) Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis. Int J Hematol 98(4):390–397

    Article  CAS  PubMed  Google Scholar 

  68. Raskob G, Gallus A, Pineo G et al (2012) Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 94(2):257–264

    Article  CAS  PubMed  Google Scholar 

  69. Li X, Sun S, Zhang W (2012) Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Chin Med J (Engl) 125(13):2339–2345

    CAS  Google Scholar 

  70. Bounameaux H, Camm A (2014) Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 74(11):1209–1231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Baumann Kreuziger L, Keenan J, Morton C, Dries D (2014) Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. Biomed Res Int 2014:583794

    Article  PubMed  PubMed Central  Google Scholar 

  72. Enriquez A, Lip G, Baranchuk A (2016) Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace 18(7):955–964

    Article  PubMed  Google Scholar 

  73. Burness C (2015) Idarucizumab: first global approval. Drugs 75(18):2155–2161

    Article  CAS  PubMed  Google Scholar 

  74. Das A, Liu D (2015) Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol 4:25

    Article  PubMed  PubMed Central  Google Scholar 

  75. Siegal D, Curnutte J, Connolly S et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373(25):2413–2424

    Article  CAS  PubMed  Google Scholar 

  76. Abo-Salem E, Becker R (2016) Reversal of novel oral anticoagulants. Curr Opin Pharmacol 27:86–91

    Article  CAS  PubMed  Google Scholar 

  77. Spyropoulos A, Al-Badri A, Sherwood M, Douketis J (2016) Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 14(5):875–885

    Article  CAS  PubMed  Google Scholar 

  78. Faraoni D, Levy J, Albaladejo P, Samama C (2015) Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care 19:203

    Article  PubMed  PubMed Central  Google Scholar 

  79. Heidbuchel H, Verhamme P, Alings M et al (2015) Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non- valvular atrial fibrillation. Europace 17(10):1467–1507

    Article  PubMed  Google Scholar 

  80. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y et al (2013) Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP)—March 2013. Arch Cardiovasc Dis 106(6–7):382–393

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Οrthopedics, University Hospital of Ioannina, Stavros Niarchos Avenue, 45500, Ioannina, Greece

    Dimitrios V. Papadopoulos, Ioannis Kostas-Agnantis, Ioannis Gkiatas, Andreas G. Tsantes, Panagiota Ziara & Anastasios V. Korompilias

  2. Κaraoli Kai Dimitriou 5, 45332, Ioannina, Epirus, Greece

    Dimitrios V. Papadopoulos

Authors
  1. Dimitrios V. Papadopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ioannis Kostas-Agnantis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ioannis Gkiatas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas G. Tsantes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Panagiota Ziara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anastasios V. Korompilias
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitrios V. Papadopoulos.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papadopoulos, D.V., Kostas-Agnantis, I., Gkiatas, I. et al. The role of new oral anticoagulants in orthopaedics: an update of recent evidence. Eur J Orthop Surg Traumatol 27, 573–582 (2017). https://doi.org/10.1007/s00590-017-1940-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00590-017-1940-x

Keywords

Search

Navigation